The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration

Author(s): Massimiliano Berretta*, Carmela Romano, Raffaele Di Francia, Chiara De Diviitis, Vincenzo Canzonieri, Michele Caraglia, Gaetano Facchini, Guglielmo Nasti

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 5 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Gastrointestinal (GI) tumors are among the leading cause of death in cancer patients worldwide. Particularly, gastric cancer (GC) is the third cause of cancer deaths, whereas esophageal neoplasm is the eighth leading most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also, Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comprehensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches have contributed to improving the outcome in these cancer diseases. During the past few years, remarkable progress in molecular biology of malignancy, the discovery of specific targets, and the resulting development of systemic drugs that block critical kinases and several molecular pathways have all contributed to progress in cancer treatment, also in GI non-colorectal cancer treatment.

Keywords: Gastrointestinal cancers, target therapy, clinical aspects, treatment, prognostic factors, metastases, costs.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [430 - 441]
Pages: 12
DOI: 10.2174/1568009617666170208162058
Price: $65

Article Metrics

PDF: 37